Traws Pharma (TRAW)
NASDAQ:TRAW
Want to see TRAW full AI Analyst Report?
Top Page
Traws Pharma
(NASDAQ:TRAW)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.00
▲(60.00% Upside)
Action:ReiteratedDate:05/09/26
The score is held down primarily by weak financial quality (persistent cash burn, negative equity, and earnings not supported by operating cash flow). Technicals are supportive with strong momentum but look overbought, while valuation appears optically cheap but is less reliable given the non-recurring nature of reported profits. The earnings call adds moderate support from defined milestones and contingent financing, offset by the FDA clinical hold and liquidity dependence on warrant exercises.
Positive Factors
No debt on balance sheet
Traws’ lack of debt meaningfully lowers mandatory interest and refinancing requirements, preserving optionality for a clinical-stage biotech. Over a 2–6 month horizon this reduces near-term solvency pressure and gives management flexibility to prioritize R&D and regulatory work without immediate debt-service constraints.
Negative Factors
Negative shareholders' equity
Negative equity reflects accumulated losses or write-downs that impair balance-sheet resilience. Over months this constrains strategic options: it weakens negotiating leverage with partners, raises governance/fiduciary scrutiny, and can complicate equity financing or registration-based financings that the company depends on.
Read all positive and negative factors
Positive Factors
Negative Factors
No debt on balance sheet
Traws’ lack of debt meaningfully lowers mandatory interest and refinancing requirements, preserving optionality for a clinical-stage biotech. Over a 2–6 month horizon this reduces near-term solvency pressure and gives management flexibility to prioritize R&D and regulatory work without immediate debt-service constraints.
Read all positive factors
Traws Pharma (TRAW) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.03M
Dividend YieldN/A
Average Volume (3M)206.36K
Price to Earnings (P/E)1.0
Beta (1Y)0.26
Revenue Growth1134.51%
EPS GrowthN/A
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding15,150,669
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue5.06
Enterprise Value/Gross Profit5.06
Enterprise Value/Ebitda-1.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.93
Revenue Forecast (FY)N/A
Traws Pharma Business Overview & Revenue Model
Company Description
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COV...
How the Company Makes Money
null...
Traws Pharma Earnings Call Summary
Earnings Call Date:Mar 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.Positive Updates
Completed $60 million Private Financing
Announced a private financing providing up to $60.0M in potential gross proceeds (including $10M upfront). Structure includes milestone-based Series A ($10M), Series B ($10M) and a Series C common warrant ($30M, 3-year term) with an accelerated feature if stock trades at 2x the deal price for 30 consecutive days.
Negative Updates
FDA IND Clinical Hold Due to Toxicology Concerns
FDA placed the Investigational New Drug (IND) filing on clinical hold over toxicology data package concerns. Company plans to repeat/submit additional assays and engage FDA; this creates a material risk of delay for U.S. development with a target to advance in the U.S. in late 2026 only if resolved.
Read all updates
Q4-2025 Updates
Positive
Negative
Completed $60 million Private Financing
Announced a private financing providing up to $60.0M in potential gross proceeds (including $10M upfront). Structure includes milestone-based Series A ($10M), Series B ($10M) and a Series C common warrant ($30M, 3-year term) with an accelerated feature if stock trades at 2x the deal price for 30 consecutive days.
Read all positive updates
Company Guidance
Management's guidance and milestones from the call were specific and metric‑heavy: the company completed a private financing providing up to $60.0M in potential gross proceeds (including $10.0M upfront plus three warrants: Series A $10.0M exercisable on MHRA approval to run the challenge trial; Series B $10.0M exercisable after shareholder approval and announcement of challenge data; and a Series C common warrant with a 3‑year term for up to $30.0M if exercised), with the Series C having an accelerated feature if the stock trades at 2× the $1.67 deal price for 30 consecutive days (10‑day forced exercise window); management believes cash including net proceeds and fully‑exercised milestone warrants is sufficient to fund planned expenses into Q1 2027. Financials cited: cash, cash equivalents and short‑term investments of ~$3.8M as of 12/31/2025 (vs $21.3M at 12/31/2024), FY2025 revenue $2.8M (vs $0.226M in 2024), net income $9.2M (or $0.83 basic / $0.82 diluted per share) vs a $166.5M loss ($35.21/share) in 2024, R&D expense $12.1M (vs $12.8M), G&A $8.5M (vs $12.3M), and acquired IPR&D $0 (vs $117.5M). Clinical and development guidance: initiate a UK human challenge prophylaxis trial at hVIVO starting in June pending MHRA review (30‑day clock), complete a Phase I bridging study in Australia to confirm a ~30% increase in exposure with the new compressed tablet (prior data showed plasma >EC90 for >3 weeks and a 28‑day coverage target), while the IND submitted in January is on clinical hold by FDA for toxicology issues that the company is addressing with an objective to resume U.S. development in late 2026.Traws Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.79M | 226.00K | 226.00K | 226.00K | 226.00K |
| Gross Profit | 2.79M | 214.00K | 226.00K | 226.00K | 226.00K |
| EBITDA | -17.81M | -166.51M | -20.28M | -19.61M | -16.48M |
| Net Income | 9.17M | -54.67M | -18.95M | -18.96M | -16.16M |
Balance Sheet | |||||
| Total Assets | 10.62M | 24.96M | 22.68M | 39.37M | 55.48M |
| Cash, Cash Equivalents and Short-Term Investments | 3.82M | 21.34M | 20.82M | 38.76M | 55.07M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 11.25M | 56.59M | 12.01M | 11.06M | 9.36M |
| Stockholders Equity | -629.00K | -31.63M | 10.67M | 28.31M | 46.12M |
Cash Flow | |||||
| Free Cash Flow | -20.77M | -29.79M | -17.95M | -16.29M | -19.49M |
| Operating Cash Flow | -18.18M | -29.79M | -17.93M | -16.29M | -19.49M |
| Investing Cash Flow | -2.58M | -3.65M | -14.00K | 0.00 | 0.00 |
| Financing Cash Flow | 3.20M | 33.98M | 0.00 | 0.00 | 55.56M |
Traws Pharma Technical Analysis
Negative
1.25
Price Trends
1.76
Negative
1.85
Negative
1.89
Negative
Market Momentum
-0.15
Positive
33.17
Neutral
26.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAW, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.69, below the 50-day MA of 1.76, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 33.17 is Neutral, neither overbought nor oversold. The STOCH value of 26.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRAW.
Traws Pharma Risk Analysis
Traws Pharma disclosed 46 risk factors in its most recent earnings report. Traws Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Traws Pharma Peers Comparison
UnderperformOutperform
Sector (51)
TRAW
Traws Pharma
2.02
0.63
45.32%
LSTA
Lisata Therapeutics
3.26
1.04
46.58%
LEXX
Lexaria Bioscience
0.60
-0.47
-43.81%
HOTH
Hoth Therapeutics
0.66
-0.27
-29.03%
APLM
Apollomics
14.65
9.51
185.02%
Traws Pharma Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Traws Pharma Reports 2025 Results, Secures PIPE Financing
Positive
Apr 15, 2026
On April 15, 2026, Traws Pharma reported its full-year 2025 results and highlighted progress across its pipeline, led by tivoxavir marboxil (TXM) for influenza and ratutrelvir for COVID-19. The company is running a Phase 1 bridging study in Austra...
Business Operations and StrategyPrivate Placements and Financing
Traws Pharma Secures PIPE Financing for Influenza Trial
Positive
Apr 15, 2026
On April 15, 2026, Traws Pharma announced that it had priced a private investment in public equity (PIPE) offering of approximately $10 million in common stock and pre-funded warrants, alongside Series A, B and C warrants that could deliver up to ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Traws Pharma Highlights Positive Ratutrelvir Phase 2 COVID-19 Data
Negative
Feb 19, 2026
On February 19, 2026, Traws Pharma reported completion of the clinical analysis of a 90-patient open-label Phase 2 study of ratutrelvir versus PAXLOVID in mild-to-moderate COVID-19, including a separate arm of PAXLOVID-ineligible patients at eleva...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.